Month: February 2025

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental...

Healthcare IT Market to Grow by USD 215.4 Billion from 2025-2029, Driven by Service Quality and Efficiency Focus, with AI Impact on Market Trends – Technavio

NEW YORK, Feb. 7, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global healthcare IT market size...

Restart Life Sciences Corp. Relies on Exception Under CSE Policy 4.6(2)(b) for Previously Closed Private Placement and Debt Settlement Transactions and Announces Debt Settlement Transaction

Hyperfine Reports on Growing Evidence for the Use of Swoop® System Images in Stroke Diagnosis Presented at the 2025 International Stroke Conference

Two presentations at ISC build on a growing body of data demonstrating the value of AI-powered portable MR images in...

error: Content is protected !!